|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM160238552 |
| 003 |
DE-627 |
| 005 |
20231223085717.0 |
| 007 |
tu |
| 008 |
231223s2006 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0534.xml
|
| 035 |
|
|
|a (DE-627)NLM160238552
|
| 035 |
|
|
|a (NLM)16426893
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Troadec, Samuel
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Biological activities on T lymphocytes of a baculovirus-expressed chimeric recombinant IgG1 antibody with specificity for the CDR3-like loop on the D1 domain of the CD4 molecule
|
| 264 |
|
1 |
|c 2006
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.04.2006
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A baculovirus-expressed chimeric recombinant IgG1 (rIgG1) antibody, with Cgamma1 and Ckappa human constant domains, was derived from the murine monoclonal antibody (mAb) 13B8.2, which is specific for the CDR3-like loop of the CD4 molecule and which inhibits HIV-1 replication. Chimeric rIgG1 antibody 13B8.2 blocked, in a dose-dependent manner, antigen presentation through inhibition of subsequent IL-2 secretion by stimulated T cells. The one-way mixed lymphocyte reaction was abrogated by previous addition of baculovirus-produced rIgG1 13B8.2 in the T-cell culture. Anti-proliferative activity of rIgG1 was demonstrated on CD3-activated CD4+ T lymphocytes from healthy donors, such effect being associated with reduced IL-2 secretion of activated T cells. On the other hand, no proliferation inhibition was observed on CD4+ T lymphocytes activated with phorbol ester plus ionomycin, suggesting that rIgG1 13B8.2 preferentially acts on a proximal TCR-induced signaling pathway. Treatment of DBA1/J human CD4-transgenic mice with 100 microg of recombinant antibody for three consecutive days led to in vivo recovery of rIgG1 antibody 13B8.2 both coated on murine T lymphocytes and free in mouse serum, without CD4 depletion or down-modulation. These findings predict that the baculovirus-expressed chimeric rIgG1 anti-CD4 antibody 13B8.2 is a promising candidate for immunotherapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a CD3 Complex
|2 NLM
|
| 650 |
|
7 |
|a CD4 Antigens
|2 NLM
|
| 650 |
|
7 |
|a Epitopes
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-2
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Fusion Proteins
|2 NLM
|
| 650 |
|
7 |
|a Ionomycin
|2 NLM
|
| 650 |
|
7 |
|a 56092-81-0
|2 NLM
|
| 650 |
|
7 |
|a Tetradecanoylphorbol Acetate
|2 NLM
|
| 650 |
|
7 |
|a NI40JAQ945
|2 NLM
|
| 700 |
1 |
|
|a Bès, Cédric
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chentouf, Myriam
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nguyen, Brigitte
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Briant, Laurence
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jacquet, Chantal
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chebli, Karim
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pugnière, Martine
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Roquet, Françoise
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cerutti, Martine
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chardès, Thierry
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 119(2006), 1 vom: 28. Apr., Seite 38-50
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:119
|g year:2006
|g number:1
|g day:28
|g month:04
|g pages:38-50
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 119
|j 2006
|e 1
|b 28
|c 04
|h 38-50
|